Cargando…
Monkeypox Virus Cross-Neutralizing Antibodies in Clinical Trial Participants Vaccinated With Modified Vaccinia Virus Ankara Encoding Middle East Respiratory Syndrome–Coronavirus Spike Protein
Modified vaccinia virus Ankara (MVA) is used as a vaccine against monkeypox virus and as a viral vaccine vector. MVA-MERS-S is a vaccine candidate against Middle East respiratory syndrome (MERS)–associated coronavirus. Here, we report that cross-reactive monkeypox virus neutralizing antibodies were...
Autores principales: | Raadsen, Matthijs P, Dahlke, Christine, Fathi, Anahita, Lamers, Mart M, van den Doel, Petra, Zaeck, Luca M, van Royen, Martin E, de Bruin, Erwin, Sikkema, Reina, Koopmans, Marion, van Gorp, Eric C M, Sutter, Gerd, de Vries, Rory D, Addo, Marylyn M, Haagmans, Bart L |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469103/ https://www.ncbi.nlm.nih.gov/pubmed/36857443 http://dx.doi.org/10.1093/infdis/jiad052 |
Ejemplares similares
-
Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial
por: Koch, Till, et al.
Publicado: (2020) -
Recombinant vesicular stomatitis virus vector vaccines for WHO blueprint priority pathogens
por: Fathi, Anahita, et al.
Publicado: (2019) -
Recombinant Modified Vaccinia Virus Ankara Expressing Glycoprotein E2 of Chikungunya Virus Protects AG129 Mice against Lethal Challenge
por: van den Doel, Petra, et al.
Publicado: (2014) -
Modified Vaccinia virus Ankara but not vaccinia virus induces chemokine expression in cells of the monocyte/macrophage lineage
por: Lehmann, Michael H, et al.
Publicado: (2015) -
Persistence of MERS-CoV-spike-specific B cells and antibodies after late third immunization with the MVA-MERS-S vaccine
por: Weskamm, Leonie M., et al.
Publicado: (2022)